Psychiatric Times

04/22/2026

The American Foundation for Su***de Prevention and The Jed Foundation (JED) have shared their intent to combine and become the AFSP/JED, which would be the nation’s largest nonprofit dedicated to su***de prevention across the lifespan.

This merger is expected to be completed by fall of 2026, subject to the approval by the New York State Attorney General.

AFSP and JED plan a 2026 merger to form the largest US su***de prevention nonprofit, uniting research, youth mental health programs, advocacy, and community support.

04/22/2026

Expanded phase 2a results for EMP-01 in adults with social anxiety disorder demonstrate clinically meaningful and consistent improvements across clinician-rated symptoms, patient-reported experience, and real-world behavioral outcomes.

Two-dose oral R‑MDMA, EMP-01, cuts social anxiety symptoms and real‑world avoidance in phase 2a study, with strong responder rates and good tolerability.

04/21/2026

Participants with narcolepsy type 1 taking once-daily alixorexton demonstrated clinically meaningful improvements in patient-reported disease severity, cognitive impairment, and fatigue, with improvements sustained through 12 to 13 weeks.

Vibrance-1 phase 2 results show alixorexton improves narcolepsy type 1 severity, cognition, and fatigue for 13 weeks with good tolerability.

04/20/2026

New youth substance use disorder criteria help clinicians deliver developmentally tailored, prevention-first care with coordinated family and community supports.

ASAM’s new youth SUD criteria help clinicians deliver developmentally tailored, prevention-first care with coordinated family and community supports.

04/17/2026

New evidence shows lithium adds minimal weight in bipolar disorder. https://www.psychiatrictimes.com/view/management-of-lithiums-adverse-effects-update-on-weight-gain

04/16/2026

Explore how an individualized, partner-based approach can inform treatment decisions in schizophrenia care.

This article highlights key considerations, including assessment, treatment history, and tolerability factors that may shape ongoing management. Read More: https://hubs.li/Q04c85QW0

04/15/2026

📣 Registration is now open for SoCal Psych 2026!

Join us July 10–11, 2026 in Huntington Beach, CA for the Southern California Psychiatry Conference — a focused, two‑day clinical education experience where regional experts present on managing complex psychiatric conditions and emerging treatments. Topics include major depression, substance use disorders, schizophrenia, and more.

Don’t miss this opportunity to enhance your clinical practice and connect with peers. Register today: https://hubs.li/Q04b3N_j0

04/14/2026

A new 56-week post hoc analysis from found that treatment with Lybalvi was associated with significant and durable improvement in negative symptoms of schizophrenia.

Psychiatric Times is the connection to Psychiatry and Mental Health, featuring clinical updates, expert views, and research news in multimedia formats.

04/14/2026

Almost 40% of American adults regularly watch reality TV.

These shows put therapy on camera, reducing stigma but raising ethical, privacy, and misinformation risks—and affecting both the viewers and cast.

Reality TV puts therapy on camera, reducing stigma but raising ethical, privacy, and misinformation risks—and affecting viewers and cast.

04/13/2026

The new ASAM youth criteria are redefining substance use disorder care. Our latest Q&A explores this update. https://www.psychiatrictimes.com/view/new-adolescent-substance-use-disorder-guidelines-reducing-patient-and-family-burden

04/10/2026

The April issue of Psychiatric Times is now live! This month, we take closer look at reality TV. Is it reducing stigma or raising ethical, privacy, and misinformation risks?

Download the issue now and follow along as articles are shared throughout the month.https://cdn.sanity.io/files/0vv8moc6/psychtimes/a1615c87f16ddd5dc7d5ef02d0205ffdb34fee26.pdf

04/09/2026

Deep intracranial frequency stimulation 77.5 Hz high-gamma approach was associated with statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with nonsuicidal self-injury, according to a new study.

Deep intracranial frequency stimulation 77.5 Hz high-gamma approach was associated with statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with nonsuicidal self-injury.